AstraZeneca plc (LON:AZN)‘s stock had its “overweight” rating reiterated by equities researchers at Barclays PLC in a research report issued to clients and investors on Monday. They currently have a GBX 6,000 ($76.71) price objective on the biopharmaceutical company’s stock. Barclays PLC’s price target would suggest a potential upside of 28.69% from the company’s previous close.
Several other research analysts also recently weighed in on the company. Jefferies Group LLC downgraded AstraZeneca plc from a “buy” rating to a “hold” rating and cut their price target for the company from GBX 5,350 ($68.40) to GBX 5,050 ($64.56) in a report on Monday, April 10th. Deutsche Bank AG reiterated a “buy” rating and issued a GBX 5,500 ($70.31) price target on shares of AstraZeneca plc in a report on Friday, April 7th. HSBC Holdings plc downgraded AstraZeneca plc to a “reduce” rating and set a GBX 4,500 ($57.53) price target for the company. in a report on Friday, April 7th. BNP Paribas reiterated a “neutral” rating and issued a GBX 5,300 ($67.76) price target on shares of AstraZeneca plc in a report on Monday, April 3rd. Finally, Beaufort Securities reiterated a “hold” rating on shares of AstraZeneca plc in a report on Monday, April 3rd. Five research analysts have rated the stock with a sell rating, six have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of GBX 5,057.40 ($64.66).
Shares of AstraZeneca plc (LON:AZN) opened at 4705.50 on Monday. AstraZeneca plc has a 52 week low of GBX 3,680.00 and a 52 week high of GBX 5,505.00. The stock’s market capitalization is GBX 59.54 billion. The stock’s 50 day moving average is GBX 4,807.24 and its 200 day moving average is GBX 4,567.77.
ILLEGAL ACTIVITY NOTICE: “Barclays PLC Reiterates Overweight Rating for AstraZeneca plc (AZN)” was first reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at http://sleekmoney.com/astrazeneca-plc-azn-earns-overweight-rating-from-barclays-plc/1737912.html.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/astrazeneca-plc-azn-earns-overweight-rating-from-barclays-plc/1737912.html
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.